(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 June 2012 (21.06.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/080842 A1

(51) International Patent Classification:
C07K 14/78 (2006.01) *A61K 38/39* (2006.01)
C12N 5/00 (2006.01)

(21) International Application Number:
PCT/IB2011/003258

(22) International Filing Date:
16 December 2011 (16.12.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/424,273	17 December 2010 (17.12.2010)	US
61/488,353	20 May 2011 (20.05.2011)	US
61/533,063	9 September 2011 (09.09.2011)	US
61/537,940	22 September 2011 (22.09.2011)	US
61/565,380	30 November 2011 (30.11.2011)	US
61/565,849	1 December 2011 (01.12.2011)	US

(71) Applicant *(for all designated States except US)*: **BIOLAMINA AB** [SE/SE]; Lofstroms Alle 5, Sundbyberg, S-17266 Stockholm (SE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **TRYGGVASON, Karl** [SE/SE]; Lokevagen 8A, S-18261 Djursholm (SE). **RODIN, Sergey** [RU/SE]; Sveavagen 164, Apt. J12, S-11346 Stockholm (SE).

(74) Agent: **KLEIN, Richard, M.**; Fay Sharpe LLP, The Halle Building, 5th Floor, 1228 Euclid Avenue, Cleveland, OH 44115-1843 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

[Continued on next page]

(54) Title: RECOMBINANT LAMININ-521




FIG. 8

(57) Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with a matrix of recombinant laminin-521 (laminin 11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.

WO 2012/080842 A1

— *with sequence listing part of description (Rule 5.2(a))*